Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBG vs IBO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–2 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IBG 1 – 2 IBO (3 Tie) Matrix Metrics: IBG 2 – 7 IBO

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBG carries a Unified Composite Score of 45.2/100 (HOLD) at $0.75 (N/M Forward P/E, -187.6% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin).

  • Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY).
  • Technical & Structure Timing Caution: IBG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBG vs IBO
IBG NASDAQ
Innovation Beverage Group Limited Ordinary Shares
Beverages
$0.75
-4.1% 1D
Market Cap $3.3M
TTM Revenue $2.8M
Forward P/E N/M
Beta / 30D Vol 1.10β · 126% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 43.0 Fund 59.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.1%), weak momentum, RSI 44
RSI-14: 43.5 · SMA20: $0.81 · SMA50: $0.88
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
TTM Revenue $2.6M
Forward P/E N/M
Beta / 30D Vol -6.72β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52

6-Pillar Scorecard Institutional Category Breakdown (IBG 1 – 2 IBO)

Columns: Metric · IBG · IBO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue 1.2x 17.4x
2. Growth & Scale IBO
Revenue Growth (YoY) -38.6% +16.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.8M $2.6M
Market Cap $3.3M $44.4M
3. Profitability & Quality IBG
Gross Margin 44.2% N/A
Operating Margin -187.6% -12621.0%
Net Profit Margin -223.4% 4247.4%
Return on Equity (ROE) -159.3% 71.2%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$5.1M EBITDA -$284M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage -159.3% ROE $1.18 Book/Sh · 71.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Beverages - Wineries & Distilleries Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBG (2) vs IBO (7)
Institutional Metric IBG IBO Criterion Row Edge
Market Capitalization
Scale
$3.3M $44.4M Larger Scale IBO
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.6% +16.7% Higher Growth IBO
Operating Margin (TTM)
Profitability
-187.6% -12621.0% Higher Margin IBG
Net Profit Margin
Profitability
-223.4% 4247.4% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
-159.3% 71.2% Higher ROE IBO
52-Week Range Position
Momentum
2% ($1–$6) 67% ($0–$7) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
1.10β · 126% Vol -6.72β · 120% Vol Lower Realized Risk IBO
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite IBG
Trailing 12M Revenue (USD)
Operating Scale
$2.8M $2.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · 17.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.1M EBITDA (-159.3% ROE) -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +90.64 pp
IBG: -7.43% · IBO: +83.21%
3M Horizon IBO +963.04 pp
IBG: -18.36% · IBO: +944.68%
6M Horizon IBO +820.68 pp
IBG: -8.55% · IBO: +812.13%
1Y Horizon IBO +921.77 pp
IBG: -59.02% · IBO: +862.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBG vs IBO. Trailing 12-month operating profitability (IBG -187.6% vs IBO -12621.0%) and valuation multiples (IBG N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IBG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.8M
Gross Margin44.2%
Op. Margin-187.6%
ROE / Fwd P/E-159.3% · N/M
IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.6M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBG Moat Profile Cyclical / Execution-Driven Positioning
Beverages - Wineries & Distilleries Operator
Competes within the Beverages - Wineries & Distilleries value chain with $3.3M market capitalization and -187.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $44.4M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBG vs IBO Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBG carries a Unified Composite Score of 45.2/100 (HOLD) at $0.75 (N/M Forward P/E, -187.6% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY). Technical & Structure Timing Caution: IBG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBO leads the Growth & Scale pillar: IBG posts -38.6% YoY revenue growth and +0.0% YoY earnings growth on $2.8M TTM revenue (44.2% gross margin, -187.6% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). On trailing 12-month operating scale, IBG generates $2.8M in USD-normalized revenue versus $2.6M for IBO. In operating R&D and SG&A reinvestment, IBG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.

IBG and IBO trade at balanced relative valuation multiples. IBG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported EBITDA margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBG (-159.3% ROE) versus IBO (71.2% ROE) capital efficiency.

In options market volatility and institutional positioning, IBG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 126% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.